2021 PRESENTING COMPANIES
March 11th, 2021 at the following time:
1:00PM - 5:00PM Eastern Time
AdOM Advanced Optical Methods
Founded in 2008, AdOM is a clinical development & commercial stage ophthalmic medical device company which developed a noninvasive, proprietary imaging device (Tear Film Imager - TFI). This device is designed to measure the muco-aqueous & lipid sublayers simultaneously and at a resolution depth of nanometer levels.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, ocular surface diseases and retinal diseases. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie is expanding globally, with offices in Europe and Japan, and a manufacturing facility in Ireland. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% are approved in the EU. A Phase 3 study of netarsudil ophthalmic solution is underway in Japan, in collaboration with Santen. Aerie is also pursuing additional candidates in ophthalmology, including a Phase 2b dry eye program with AR-15512 (TRPM8 agonist), and two clinical-stage retina programs, AR-1105 (dexamethasone) Sustained Release Implant and AR-13503 (Rho kinase/Protein kinase C inhibitor) Sustained Release Implant. Aerie continues to investigate assets from its proprietary library of small-molecule multi-kinase inhibitors.
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
Allotex Inc. is an ophthalmic biologics and device company developing new therapeutic solutions for improving the vision of millions of patient’s using allogeneic therapies. Allotex delivers scalable, quality-controlled vision correction and eye care products based on ethically sourced allogeneic material. Allotex is a start-up company led by Drs. David Muller and Michael Mrochen.
Hovione is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) and is currently a fully integrated supplier offering services for drug substance, drug product intermediate and drug product. With four FDA inspected sites in the USA, China, Ireland and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds. For generic pharmaceutical customers, the company offers niche API products. Hovione also provides proprietary product development and licensing opportunities for drug products. In the inhalation area, Hovione is the only independent company offering a complete range of services.
Mitotech S.A. is a Luxembourg-based clinical stage biotechnology company developing novel drugs for treatment of age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria addressed cardiolipin peroxidation inhibitors. Most advanced SkQ1-based drug product in Mitotech's pipeline is ophthalmic solution Visomitin which completed its second large clinical study in the U.S. for Dry Eye Disease (a Phase III VISTA-2 study). Other indications include Uveitis, LHON and dry AMD and are at earlier stages of clinical development.
Based in Issaquah, Washington, Olympic is a commercial stage medical device company leveraging expertise in neuromodulation and energy based technology to discover, develop and commercialize novel therapies to treat ocular diseases with high unmet needs. The company’s first product iTEAR100, cleared by FDA in 2020 is an external neuromodulation device to increase natural tear production by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Our leadership team brings extensive experience in developing and commercializing treatments for ophthalmic and other disease categories.
Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).